AbbVie Inc. outperformed its big pharma peers during the first quarter, reporting 5.2% revenue growth year-over-year, totaling just over $13bn, with notable growth in its immunology, aesthetics and neuroscience portfolios. Much of that resilience came from business brought in by its 2020 acquisition of Allergan plc, and CEO Rick Gonzalez played up the company’s diversity in presenting the Q1 results.
“We are clearly demonstrating that we have created a stronger and much more diverse company with the scale and flexibility...








